Literature DB >> 17398178

Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events.

Anil Palikhe1, Juha Sinisalo, Mikko Seppänen, Heikki Haario, Seppo Meri, Ville Valtonen, Markku S Nieminen, Marja-Liisa Lokki.   

Abstract

Acute coronary syndrome is an inflammatory disease, during which the complement cascade is activated. We assessed the complement C3 and C4 concentration ratio (C3/C4 ratio) in serum as a potential measurement to predict cardiovascular attacks. Patients with acute coronary syndrome (n=148) were followed after an initial attack for subsequent ischemic cardiovascular events (composite end point of death, myocardial infarction, recurrent unstable angina, or stroke). During the follow-up period (average 555 days), 44 patients met an end point. Blood samples were taken at hospitalization, 1 week, 3 months, and 1 year after hospital admission. Serum complement C3 and C4 concentrations and the C3/C4 ratio were analyzed. Patients with an end point had, throughout the follow-up period, a higher C3/C4 ratio than patients without these end points (repeated measures analysis of variance, p=0.007). When all traditional cardiovascular risk factors and other potential confounding factors were included in a Cox multivariate logistic regression survival analysis, the C3/C4 ratio emerged as the novel risk factor for any new cardiovascular event (odds ratio 1.33, 95% confidence interval 1.08 to 1.63, p=0.007). When the C3/C4 ratio was divided into 4 quartiles, 24% in quartiles 1 and 2 (lowest) and 48% in quartile 4 (highest) had end points during follow-up (odds ratio 3.04, 95% confidence interval 1.27 to 7.29, p=0.01). In conclusion, increased serum C3/C4 ratio is a readily available and novel marker for recurrent cardiovascular events in acute coronary syndrome. The relative increase in serum C3 protein and decrease in C4 protein could explain changes in the C3/C4 ratio.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17398178     DOI: 10.1016/j.amjcard.2006.11.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.

Authors:  Osama A Hamad; Ioannis Mitroulis; Karin Fromell; Huda Kozarcanin; Triantafyllos Chavakis; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Thromb Haemost       Date:  2015-08-13       Impact factor: 5.249

2.  MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans.

Authors:  Ming Zhang; Yunfang Joan Hou; Erdal Cavusoglu; Daniel C Lee; Rudi Steffensen; Liming Yang; Daniel Bashari; Jose Villamil; Motaz Moussa; George Fernaine; Jens C Jensenius; Jonathan D Marmur; Wilson Ko; Ketan Shevde
Journal:  Int J Cardiol       Date:  2011-12-15       Impact factor: 4.164

3.  Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.

Authors:  O A Hamad; K N Ekdahl; P H Nilsson; J Andersson; P Magotti; J D Lambris; B Nilsson
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

4.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Function of serum complement in drinking water arsenic toxicity.

Authors:  Laila N Islam; M Shamim Hasan Zahid; A H M Nurun Nabi; Mahmud Hossain
Journal:  J Toxicol       Date:  2012-03-21

6.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

7.  Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein.

Authors:  Eli Magen; Joseph Mishal; Jana Paskin; Zahava Glick; Chaim Yosefy; Mona Kidon; Menachem Schlesinger
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

Review 8.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671

9.  Cardioembolic and small vessel disease stroke show differences in associations between systemic C3 levels and outcome.

Authors:  Anna Stokowska; Sandra Olsson; Lukas Holmegaard; Katarina Jood; Christian Blomstrand; Christina Jern; Marcela Pekna
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

10.  C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease.

Authors:  Jessica Kristin Henes; Patrick Groga-Bada; Elke Schaeffeler; Stefan Winter; Luis Hack; Monika Zdanyte; Karin Mueller; Michal Droppa; Fabian Stimpfle; Meinrad Gawaz; Harald Langer; Matthias Schwab; Tobias Geisler; Dominik Rath
Journal:  Pharmgenomics Pers Med       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.